參考文獻(xiàn)/References:
[1] Zhuo Z, Li F, Chen X, et al.Mycoplasma pneumonia combined with pulmonary infarction in a child[J]. Int J Clin Exp Med,2015,8(1):1482-1486.[2] Cilloniz C, Torres A, Niederman M, et al.Community-acquired pneumonia related to intracellular pathogens[J]. Intensive Care Med,2016,42(9):1374-1386.[3] Zhang Y, Zhou Y, Li S, et al.The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in Children[J]. PLoS One,2016,11(5):e156465.[4] 田恬,趙文靜,高頌軼,等.甲潑尼龍聯(lián)合阿奇霉素治療兒童肺炎支原體大葉性肺炎的療效[J]. 藥物評價研究,2018,41(1):126-129.[5] 曹效紅.甲潑尼龍聯(lián)合阿奇霉素治療小兒難治性支原體肺炎的療效與安全性分析[J]. 國際醫(yī)藥衛(wèi)生導(dǎo)報,2016,22(12):1745-1748.[6] 王浩,楊靜容,歐靜琳.甲潑尼龍聯(lián)合阿奇霉素治療RMPP患兒的臨床效果[J]. 中南醫(yī)學(xué)科學(xué)雜志,2016,44(04):442-446.[7] Shan L S, Liu X, Kang X Y, et al.Effects of methylpredniso-lone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children[J]. World J Pediatr,2017,13(4):321-327.[8] Gong L, Xu L, Diao M, et al.Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin[J]. Eur Rev Med Pharmacol Sci,2016,20(24):5256-5260.